Earnings Alerts

Persistent Systems (PSYS) Earnings Surpass Estimates with 39% Net Income Growth in 1Q

  • Persistent Systems‘ net income for the first quarter is 4.25 billion rupees, marking a 39% increase year-over-year.
  • Net income surpassed estimates, which were projected at 4.19 billion rupees.
  • The company reported revenues of 33.3 billion rupees, up 22% from the previous year.
  • Revenue slightly missed the estimates set at 33.57 billion rupees.
  • Total costs amounted to 28.3 billion rupees, showing a 19% rise compared to the previous year.
  • Other income experienced a significant growth of 78%, totaling 546.6 million rupees.
  • Analysts provided mixed recommendations: 19 buy ratings, 11 hold ratings, and 12 sell ratings.

A look at Persistent Systems Smart Scores

FactorScoreMagnitude
Value2
Dividend3
Growth4
Resilience5
Momentum4
OVERALL SMART SCORE3.6

Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma

Based on the Smartkarma Smart Scores, Persistent Systems is positioned well for long-term growth and stability in the market. With above-average ratings in Growth, Resilience, and Momentum, the company demonstrates a strong potential for expansion and maintaining its performance even during challenging times. This indicates that Persistent Systems has the capability to steadily grow its business and navigate market fluctuations successfully.

Furthermore, while the Value score is moderate and the Dividend score is decent, the overall outlook for Persistent Systems appears positive. As a provider of outsourced software product development services including testing and professional support, the company’s solid scores across key factors suggest a promising future ahead, with opportunities for sustained growth and resilience in the competitive tech industry.


Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.


 

πŸ’‘ Before it’s here, it’s on Smartkarma

Sign Up for Free

The Smartkarma Preview Pass is your entry to the Independent Investment Research Network

  • βœ“ Unlimited Research Summaries
  • βœ“ Personalised Alerts
  • βœ“ Custom Watchlists
  • βœ“ Company Analytics and News
  • βœ“ Events & Webinars